Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19).
Umakanthan S, Sahu P, Ranade AV, Bukelo MM, Rao JS, Abrahao-Machado LF, Dahal S, Kumar H, Kv D. · 2020
Read Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). by Umakanthan S, Sahu P, Ranade AV, Bukelo MM, Rao JS, Abrahao-Machado LF, Dahal S, Kumar H, Kv D. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc10016932.txt.
Introduction
Umakanthan and colleagues review what was known about COVID-19 in a 2020 paper, covering its origin, spread, diagnosis, and care. Coronaviruses had already caused two major outbreaks in two decades. The new disease, first seen in late 2019, was spreading across the world as they wrote.
The authors explain where the virus likely came from and how it passes between people. They survey the tests used to confirm infection and the care given to patients. The paper stands as a compact record of early knowledge, written while the pandemic was still young.
Catalog record
| CREATOR | Umakanthan S, Sahu P, Ranade AV, Bukelo MM, Rao JS, Abrahao-Machado LF, Dahal S, Kumar H, Kv D. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19) By Srikanth Umakanthan, Pradeep Sahu, Anu V Ranade, Maryann M Bukelo, Joseph Sushil Rao, Lucas Faria Abrahao-Machado, Samarika Dahal, Hari Kumar, Dhananjaya KV Published in: Postgraduate Medical Journal DOI: 10.1136/postgradmedj-2020-138234 ABSTRACT Abstract Coronavirus has emerged as a global health threat due to its accelerated geographic spread over the last two decades. This article reviews the current state of knowledge concerning the origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). Historically, it has caused two pandemics: severe acute respiratory syndrome and Middle East respiratory syndrome followed by the present COVID-19 that emerged from China. The virus is believed to be acquired from zoonotic source and spreads through direct and contact transmission. The symptomatic phase manifests with fever, cough and myalgia to severe respiratory failure. The diagnosis is confirmed using reverse transcriptase PCR. Management of COVID-19 is mainly by supportive therapy along with mechanical ventilation in severe cases. Preventive strategies form the major role in reducing the public spread of virus along with successful disease isolation and community containment. Development of a vaccine to eliminate the virus from the host still remains an ongoing challenge. Keywords: Pathology, Histopathology, Education and training (see medical education & training), Medical education and training, Surgery, Transplant surgery, Hepatobiliary surgery, Basic sciences, Pathology INTRODUCTION Coronavirus (CoV) is derived from the word ‘corona’ meaning ‘crown’ in Latin.1 It causes a range of human respiratory tract infections varying from mild cold to severe respiratory distress syndrome.2 The present novel CoV disease also called as severe acute respiratory syndrome (SARS)-CoV-2 and coronavirus disease 2019 (COVID-19) is an emerging global health threat.3 The COVID-19 epidemic started from Wuhan city of China towards the end of December 2019 and since then spread rapidly to Thailand, Japan, South Korea, Singapore and Iran in the initial months.4–6 This was followed by wide viral dissemination around the world including Spain, Italy, USA, UAE and the UK.7 The WHO declared the COVID-19 outbreak as a pandemic.8 As of 6 May 2020, outbreaks and sporadic human infections have resulted in 3 732 046 confirmed cases and 261 517 deaths.7 The CoV has posed frequent challenges during its course ranging from virus isolation, detection, prevention to vaccine development.9 CoV belongs to the order Nidovirales and has the largest RNA genome.10 It is known to be acquired from a zoonotic source and typically spreads through contact and droplet transmission. The infected person presents with non-specific clinical features requiring virological detection and confirmation by molecular techniques.11–13 This article aims to give a detailed insight into the evolution, transmission and diagnosis of COVID-19. We further discuss the challenges encountered in the management of patients with COVID-19 and the current limitations in the investigational vaccine. Due to the rapidly evolving nature of COVID-19, the readers are requested to update themselves with the nature of change with this particular type of CoV. ORIGIN Historic perspective CoV was discovered during the 1960s. The Coronavirus Study Group under the International Committee on Taxonomy of Viruses used the principle of comparative genomics to further assess and partition the replicative proteins in open reading frames to identify the factors that differentiate CoV at different cluster ranks.14 15 CoV is associated with illness of varied intensity. The most severe type resulting in large-scale pandemics in the past are the SARS (in 2002–2003) and Middle East respiratory syndrome (MERS) (in 2012).16 17 Aetiology CoV are RNA viruses of the subfamily Coronavirinae. They belong to the family Coronaviridae and the order Nidovirales (nido Latin for ‘nest’). The order Nidovirales is composed of Coronaviridae, Arteriviridae, Mesovirididae and Roniviridae families.10 18 The characteristic features of Nidovirales are as follows: they (1) contain very large genomes for RNA viruses, (2) are highly replicative due to conserved genomic organisation, (3) exhibit several unique enzymatic activities and (4) have extensive ribosomal frameshifting due to the expression of numerous non-structural genes. The Coronaviridae family have two subfamilies: Coronavirinae and Torovirinae. The subfamily Coronavirinae consist of alpha CoV, beta CoV, gamma CoV and delta CoV based on genomic structure.19 Viral structure The CoV are enveloped positive single-stranded RNA viruses having the largest known viral RNA genomes of 8.4–12 kDa in size.20 The viral genomes are made up of 5ʹ and 3ʹ terminal. The 5ʹ terminal constitutes a major part of the genome and contains open reading frames, which encodes proteins responsible for viral replication. The 3ʹ terminal contains the five structural proteins, namely the spike protein (S), membrane protein (M), nucleocapsid protein (N), envelope protein (E) and the haemagglutinin-esterase (HE) protein.21 22 The S protein mediates an attachment and fusion between the virus and host cell membrane and also between the infected and adjacent uninfected cells. They are the major inducers for neutralising antibodies in a vaccine. The N protein forms RNA complexes that aid in virus transcription and assembly. The M protein is the most abundant structural protein and also defines the viral envelope shape. The E protein is the most enigmatic and the smallest of the major structural protein, which is highly expressed within the infected cell during viral replication cycle. The HE protein is responsible for receptor binding and host specificity.20 23 SARS and MERS SARS was first recognised in Guangdong province, China, in November 2002. It advanced among 30 countries, infecting 79 000 people by 2003 with a fatality of 9.5%. SARS-CoV was traced and isolated from Himalayan palm civets found in a livestock market in Guangdong, China.16 24 The zoonotic origin of SARS was also discovered in racoon dogs, ferret badgers and in humans working at the same market. These market animals were therefore intermediate hosts that increased the transmission of virus to humans.15 24 Thereon, in 2012, Jeddah, Saudi Arabia, a patient presented with respiratory illness consistent with pneumonia along with features of renal failure.25 The patient’s sputum analysis was done by reverse transciptase (RT-PCR) using pan-CoV primers revealing the viral RNA to be MERS-CoV.26 As of July 2013, 91 patients were infected with MERS-CoV and had a high fatality rate of 34%. Bats and Arabian dromedary camels were identified as potential hosts for MERS-CoV. Intermediate host reservoir species were also seen in goats, sheep and cows.27 28 Novel CoV In view of taxonomical classification, SARS-CoV-2 (COVID-19) is one among many other viruses in the species, SARS-related CoV. However, SARS-CoV and SARS-CoV-2 vary in terms of disease spectrum, modes of transmission and also diagnostic methods.9 28 The recent report on a cluster cases having respiratory illness in Wuhan, Central China, was followed by a global spread of the disease in a very short duration of time. The samples (oral and anal swabs, blood and broncho-alveolar fluid lavage) from patients admitted to the intensive care unit of Wuhan Jinyintan Hospital were sent to Wuhan Institute of Virology. Pan-CoV PCR primers were used and these samples were positive for CoV.1–3 29 This was followed by metagenomics analysis and genomic sequencing study. The results revealed that this virus was identical (79.6%) to the genetic sequence of SARS-CoVBJ01 leading the WHO to call it novel CoV-2019 (2019-nCoV).30 31 TRANSMISSION AND PATHOGENESIS Zoonosis CoVs are widespread among birds and mammals with cements bats forming the major evolutionary reservoir and ecological drivers of CoV diversity.32